Start Over

One-year lung function decline in sarcoidosis.

Authors :: Tanizawa K
Handa T
Nagai S
Ikezoe K
Kubo T
Yokomatsu T
Ueda S
Fushimi Y
Ogino S
Hirai T
Izumi T
Source :: Respiratory investigation [Respir Investig] 2024 Jan; Vol. 62 (1), pp. 9-12. Date of Electronic Publication: 2023 Nov 03.
Publication Year :: 2024
Abstract: Background: The definition of progressive pulmonary fibrosis is based on a 1-year lung function decline. Objectives: To evaluate the epidemiology and clinical relevance of 1-year lung function decline in sarcoidosis. Methods: A retrospective observational study at a general sarcoidosis clinic. Results: Of the 198 patients, 42 (18.4 %) had a 1-year lung function decline (absolute 12-month decline in percentage predicted forced vital capacity [%FVC] of ≥5 % or percentage predicted diffusion capacity for carbon monoxide [%DLCO] of ≥10 %). A 1-year lung function decline was associated with a 2-year lung function decline (a relative 24-month decline in %FVC of ≥10 % or %DLCO of ≥15 %), which occurred in 13 (7.4 %) of the 175 patients with 24-month follow-up results. A 1-year lung function decline was not associated with survival; a 2-year lung function decline predicted mortality. Conclusions: Compared with a 24-month decline, a 12-month decline in lung function did not predict worse survival in sarcoidosis. Competing Interests: Conflict of interest Kiminobu Tanizawa received a research grant from the FUJIFILM Corporation; Tomohiro Handa received a research grant from the FUJIFILM Corporation and belongs to an endowed department sponsored by Teijin Pharma Ltd; Sonoko Nagai has no conflicts of interest; Kohei Ikezoe received a research grant from the FUJIFILM Corporation; Takeshi Kubo has no conflicts of interest; Takafumi Yokomatsu has no conflicts of interest; Seigen Ueda has no conflicts of interest; Yasutaka Fushimi has no conflicts of interest; Shumpei Ogino has no conflicts of interest; Kizuku Watanabe has no conflicts of interest; Yoshinari Nakatsuka belonged to an endowed department sponsored by Philips Respironics, Teijin Pharma Ltd., Fukuda Denshi Inc., and Fukuda Lifetec Keiji; Toyohiro Hirai received a research grant from the FUJIFILM Corporation; and Takateru Izumi has no conflicts of interest. (© 2023 Published by Elsevier B.V. on behalf of The Japanese Respiratory Society.)